

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) [[A]] In a subject with extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, a method of treatment for treating or reducing said extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, in a subject comprising administering to a subject an effective amount of a composition comprising Thymosin β 4 (T β 4) or oxidized T β 4 in an amount effective so as to inhibit said extracellular matrix build-up in a body tissue or a bodily fluid transport vessel of said subject.
2. (Previously Presented) The method of claim 1 wherein said peptide agent comprises T β 4.
3. (Original) The method of claim 1 wherein said peptide agent is administered to said subject at a dosage within a range of about 1-10 mg/kg body weight of said subject.
4. (Original) The method of claim 1 wherein said agent is administered by direct administration to said tissue, or by intravenous, intraperitoneal, intramuscular, subcutaneous, inhalation, transdermal or oral administration, to said subject.
5. (Original) The method of claim 1 wherein said composition is administered systemically.

6. (Original) The method of claim 1 wherein said composition is administered directly.
7. (Original) The method of claim 1 wherein said composition is comprised of a matrix, adhesive, solution, gel, crème, paste, lotion, spray, suspension, dispersion, salve, hydrogel or ointment formulation.
8. (Original) The method of claim 1 wherein said peptide agent is a recombinant or synthetic peptide.
9. (Withdrawn) The method of claim 1 wherein said agent is an antibody.
10. (Previously Presented) The method of claim 1 wherein said T β 4 is administered in conjunction with utilization in said subject of at least one of an arterial stent, venous stent, cardiac catheterization, corroded stent, aortic stent, pulmonary stent, angioplasty, bypass surgery or neurosurgery.
11. (Original) The method of claim 1 wherein said matrix build-up comprises plaque present in at least one of a coronary vessel, heart valve or heart septa of said subject.
12. (Previously Presented) The method of claim 1 wherein said T β 4 is linked to a physiologically acceptable adhesive.
13. (Previously Presented) The method claim 1 wherein said T β 4 is administered to said subject so as to treat, prevent, inhibit or reduce stenosis or restenosis in said subject.

14. (Previously Presented) The method of claim 13 wherein said T β 4 is administered at least one of prior to, during or following angioplasty in said subject.

15-17. (Canceled)

18. (Previously Presented) The method of claim 1 wherein said T β 4 is administered, in combination with at least one plaque-reducing agent or cholesterol-reducing agent.

19. (Withdrawn) A mechanical medical device for utilization in a body of a subject, said device being linked to a peptide agent comprising a polypeptide comprising amino acid sequence LKKTET or a conservative variant thereof, KLKKTET, LKKTETQ, Thymosin β 4 (T β 4), oxidized T β 4, N-terminal variants of T β 4, C-terminal variants of T β 4, T β 9, T β 10, T β 11, T β 12, T β 13, T β 14, T β 15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, β -actinin or acumentin.

20. (Withdrawn) The device of claim 19, comprising an arterial stent, a venus stent, a carotid stent, an aortic stent or a pulmonary stent.

21. (Withdrawn) The device of claim 19 wherein said peptide agent is covalently linked to said device, said peptide agent is present in a matrix linked to said device, said peptide agent is coupled by an adhesive to said device, or said peptide agent is present in a gel linked to said device.

22. (Withdrawn) The device of claim 19 wherein said peptide agent is T β 4.

23. (Withdrawn) A method of medical treatment comprising providing the medical device of claim 19 in a body of a subject, said medical device being linked to said peptide agent.
24. (Withdrawn) The method of claim 23 wherein said device is an arterial stent, a venus stent, a carotid stent, an aortic stent or a pulmonary stent.
25. (Withdrawn) The method of claim 23 wherein said peptide agent is T β 4.
26. (Withdrawn) A method of medical treatment comprising introducing a mechanical medical device into a body of a subject, and administering to the subject a peptide agent comprising a polypeptide comprising amino acid sequence LKKTET or a conservative variant thereof, KLKKTET, LKKTETQ, Thymosin β 4 (T β 4), oxidized T β 4, N-terminal variants of T β 4, C-terminal variants of T β 4, T β 9, T β 10, T β 11, T β 12, T β 13, T β 14, T β 15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, β -actinin or acumentin, wherein said administering is at least one of before, during or after introducing said medical device into said subject.
27. (Withdrawn) The method of claim 26 wherein said medial device is utilized in catheterization.
28. (Withdrawn) The method of claim 26 wherein said polypeptide is thymosin beta 4.
29. (Withdrawn) The method of claim 1 wherein said polypeptide is thymosin beta 4.